The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL Cells into the circulation

Cancer

Volumn 116, Issue 9, 2010, Pages 2201-2207

  Zent, Clive S ^a   LaPlant, Betsy R ^a   Johnston, Patrick B ^a   Call, Timothy G ^a   Habermann, Thomas M ^a   Micallef, Ivana N ^a   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chronic lymphocytic leukemia small lymphocytic lymphoma; Everolimus; Inhibitor; Mobilization; mTOR; Rapamycins

Indexed keywords

EVEROLIMUS;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CELL MOTILITY; CELLULITIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; INFECTION; LEUKOPENIA; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH NODES; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RECURRENCE; SIROLIMUS;

EID: 77951450222     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25005     Document Type: Article

References (26)

1. Zent CS, Kyasa MJ, Evans R, Schichman SA. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer. 2001;92:1325-1330.
2. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia. Blood. 2007;109:405-411.
3. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088. (Pubitemid 46211313)
4. Gribben JG. Salvage therapy for CLL and the role of stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2005:292-298.
5. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070-4078. (Pubitemid 46211312)
6. Kurmasheva RT, Huang S, Houghton PJ. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer. 2006;95:955-960. (Pubitemid 44606818)
7. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19:6680-6686. (Pubitemid 32197708)
8. Aleskog A, Norberg M, Nygren P, et al. Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination. Leuk Lymphoma. 2008;49:2333-2343.
9. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347-5356. (Pubitemid 46206988)
10. Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008;113:508-514.
11. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755-764.
12. Ringshausen I, Peschel C, Decker T. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option. Leuk Lymphoma. 2005;46:11-19.
13. Bennett F, Rawstron A, Plummer M, et al. B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle. Br J Haematol. 2007;139:600-604. (Pubitemid 350043808)
14. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004;100:657-666. (Pubitemid 38176841)
15. Decker T, Hipp S, Ringshausen I, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood. 2003;101:278-285. (Pubitemid 36025919)
16. Decker T. Is mTOR inhibition a therapeutic option in chronic lymphocytic leukemia? Leuk Lymphoma. 2008;49:2235-2236.
17. Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND, Raza A. Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch." Leuk Res. 2007;31:899-906.
18. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997. (Pubitemid 26189840)
19. Muller-Hermelink HK, Catovsky D, Montserrat E, Harris NL. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Jaffe E, Harris N, Stein H, Vardiman J, eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:127-130.
20. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
21. Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol. 2009;88:221-227.
22. Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med. 2008;264:549-562.
23. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 1996;93:151-153. (Pubitemid 26132394)
24. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554-3561. (Pubitemid 34534522)
25. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281. (Pubitemid 38525651)
26. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med. 2002;347:452-453. (Pubitemid 34851846)